TMCnet News
PWRM, CRTX, & ZGEN Making Products to Heal by Stock-PR.comStock-PR Reporting FREE Daily Stock Alerts From Stock-PR.com ________________________________________ Power3 Medical Products, Inc. (OTCBB:PWRM) reported that, in collaboration with Lourdes R. Bosquez, MD, Power3 has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer's disease patients compared to patients treated with the widely used anti-dementia drugs Aricept®, Exelon®, and Namenda®. These results relate to the genetically distinct groups of Alzheimer's disease patients, i.e., those individuals who possess the Alzheimer's high-risk gene for Apolipoprotein E4 and those who do not possess the gene. NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer's disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms. Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world's most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of Power3's NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist Power3 greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs. ?This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,? said Dr. Bosquez. Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, ?This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer's disease, and for other diseases as well.? Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro?, a proteomic blood serum test for the early detection of breast cancer for which Power3 has completed Phase I clinical trials, and NuroPro®, a serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual's risk for developing disease later in life, a patient's likelihood of responding to a particular drug, a patient's risk of disease progression and disease recurrence, to measure a patient's exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity. Cornerstone Therapeutics Inc. (Nasdaq:CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, last week reported that its product candidate CRTX-067 is an ANDA filing for a generic 10 mg chlorpheniramine polistirex/8 mg hydrocodone polistirex suspension product that will be a generic substitute for the product currently sold under the Tussionex brand name by UCB, Inc. "This product offers substantial revenues in 2011 and exciting growth potential," said Craig A. Collard, Cornerstone's President and Chief Executive Officer. "Resolving the uncertainty around 067 underlines Cornerstone's commitment to focus on the development of its cough and cold franchise. We continue to expect that the expedited review of 067 will result in FDA approval in early 2011." This report immediately follows the announcement of Cornerstone's decision to cease manufacturing and distribution of marketed unapproved drugs, and to focus its growth strategy exclusively on products with long-term revenue potential, intellectual property and NDA or ANDA approvals. Cornerstone Therapeutics Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. Cornerstone currently promotes multiple marketed products in the United States to respiratory-focused physicians, key retail pharmacies and hospitals with Cornerstone's specialty sales forces. Cornerstone also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of Cornerstone's strategy are to in-license or acquire rights to under-promoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of Cornerstone's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through Cornerstone's specialty sales forces; and maintain and strengthen the intellectual property position of Cornerstone's currently marketed products, newly acquired products and product candidates. ZymoGenetics, Inc. (NASDAQ:ZGEN) reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, ZymoGenetics' net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses. ?We are experiencing substantial momentum in all aspects of our business,? said Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics. ?Phase 2b randomized comparative clinical trials for two of our product candidates are now underway in hepatitis C and melanoma. Encouraging results from our Phase 2a trials in those diseases indicate we could have game-changing compounds with tremendous potential to assist patients in need. In addition, RECOTHROM sales are steadily growing and our financial trends continue to improve.? Revenues for the second quarter of 2010 increased to $37.7 million from $22.6 million for the second quarter of 2009. The increase was attributable to a $9.4 million increase in collaboration and license revenues and nearly a doubling of net sales of RECOTHROM® Thrombin, topical (Recombinant). Net U.S. sales of RECOTHROM were $11.9 million for the second quarter of 2010 compared to $6.0 million for the second quarter of 2009, an increase of 98%. Compared to the first quarter of 2010, net sales in the second quarter increased by 32%. In the second quarter of 2010, both RECOTHROM market share and hospital unit demand increased versus the first quarter of 2010. Collaboration and license revenues were $25.6 million for the second quarter of 2010 compared to $16.3 million in the second quarter of the prior year. The increase was primarily related to recognition of revenue associated with the December 2009 license agreement with Novo Nordisk for IL-21 antagonists and incremental revenues recognized related to ZymoGenetics' PEG-Interferon lambda collaboration with Bristol-Myers Squibb due to advancement and expansion of clinical development activities. These increases were partially offset by reduced revenues from collaborations with Bayer and Merck Serono, both of which ended in the fourth quarter of 2009. Costs and expenses for the second quarter of 2010 decreased by 18% to $38.9 million from $47.2 million for the second quarter of 2009. Overall, the decrease was attributable to expense reductions resulting from ZymoGenetics' 2009 restructuring, which is expected to continue to benefit ZymoGenetics' expense structure in coming quarters. Research and development expenses for the second quarter of 2010 were $23.7 million, a decrease of $5.4 million from the 2009 quarter. The decrease was primarily attributable to a reduction of headcount related expenses in 2010 resulting from the reductions in force made in April and December 2009 and related severance expenses incurred in the second quarter of 2009. These savings were partially offset by an increase in costs related to the PEG-Interferon lambda development program, which advanced to Phase 2b clinical testing in the second quarter of 2010. Selling, general and administrative expenses for the second quarter of 2010 were $12.6 million, compared to $16.7 million for the second quarter of 2009. The decrease was primarily related to reduced headcount related expenses in 2010, severance expenses incurred in the second quarter of 2009 and the discontinuation of Bayer commission expense, which is now being charged against a liability recorded in December 2009. As of June 30, 2010, ZymoGenetics had $205.5 million of cash, cash equivalents and short-term investments. Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading shares for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Sign Up For Free Stock Alerts At http://stock-pr.com/signup ________________________________________ Be Sure To Visit stock-pr.ning.com ********************************************************************** The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments. |